Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration, FDA, has approved Brekiya injection, the first and only dihydroergotamine autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. “We are thrilled to offer the first and only ready-to-use autoinjector for patients suffering from acute migraine and cluster headaches. Physicians are familiar with DHE, which is an effective and well-established therapy that provides sustained relief for headaches. Our single-dose autoinjector represents an innovative therapeutic option for patients that allows for quick self-administration of the medication during these painful attacks without visiting the emergency room,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting
- Amneal Pharmaceuticals, Apiject announce strategic collaboration
- Amneal Pharmaceuticals Reports Strong Q1 2025 Results
- Amneal Pharma’s Earnings Call Highlights Strong Growth
- Amneal Pharmaceuticals Reports Strong Q1 2025 Financial Results